Browse Studies — Arctuva

Phase 3

A Randomised, Open-label, Phase III Study of Torvutatug Samrotecan With or Without Bevacizumab Versus Standard of Care as Second- or Third-Line Maintenance Treatment in Participants With Platinum-sensitive Relapsed Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (TREVI-OC-03)

The purpose of this study is to measure the efficacy and safety of torvutatug samrotecan (torvu-sam) with or without bevacizumab compared to standard of care (…

Platinum-sensitive Relapsed Epithelial Ovarian CancerPlatinum-sensitive Relapsed Fallopian Tube CancerPlatinum-sensitive Relapsed Primary Peritoneal Cancer

Estimated

~$50 – $2,250

Actual pay is set by the research site.